Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer

Abstract Purpose Nivolumab plus ipilimumab (Nivo-Ipi) combination therapy is an effective first-line treatment for advanced non-small cell lung cancer (NSCLC). However, its effectiveness and feasibility in elderly patients (aged ≥ 75 years) remain unclear. This study aimed to investigate the efficac...

Full description

Saved in:
Bibliographic Details
Main Authors: Satoshi Endo, Hisao Imai, Atsuto Mouri, Kasumi Tsukamoto, Kenji Masaki, Kosuke Hashimoto, Yu Miura, Ayako Shiono, Ou Yamaguchi, Junichi Nakagawa, Kyoichi Kaira, Kunihiko Kobayashi, Hiroshi Kagamu
Format: Article
Language:English
Published: Springer 2025-01-01
Series:Journal of Cancer Research and Clinical Oncology
Subjects:
Advanced non-small cell lung cancer
Elderly patients
First-line treatment
Immune checkpoint inhibitor
Ipilimumab
Nivolumab
Online Access:https://doi.org/10.1007/s00432-025-06089-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1007/s00432-025-06089-x

Similar Items